China Seen As The Prize In The Race For HCV Dominance
As Gilead and AbbVie battle for new hepatitis C treatment options, Roche is hoping a trailing product can find a home in China, where genotype 1b HCV is most prevalent.
As Gilead and AbbVie battle for new hepatitis C treatment options, Roche is hoping a trailing product can find a home in China, where genotype 1b HCV is most prevalent.